With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

After first claiming an FDA clearance last year for its mixed reality brain surgery navigation platform, Zeta Surgical has ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate | This ...